Debashis Sarker

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Advanced Cancer

Dna Damage Response

Top Venues

Journal of neuroendocrinology

British journal of cancer

Science advances

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Jessica Hooper, Nikie Jervis, Lucy Morgan, Vivienne Beckett, Philippa Hand, Kate Higgs, Alia Munir, Jenny Prinn, David Mark Pritchard, Debashis Sarker, Rajaventhan Srirajaskanthan, Catherine Bouvier Ellis
Neuroendocrine neoplasms: Consensus on a patient care pathway. Journal of neuroendocrinology 36 (4) (2024)
Jessica Hooper, Nikie Jervis, Lucy Morgan, Vivienne Beckett, Philippa Hand, Kate Higgs, Alia Munir, Jenny Prinn, David Mark Pritchard, Debashis Sarker, Rajaventhan Srirajaskanthan, Catherine Bouvier Ellis
Neuroendocrine neoplasms: Consensus on a patient care pathway. Journal of neuroendocrinology 36 (4) (2024)
Jessica Hooper, Nikie Jervis, Lucy Morgan, Vivienne Beckett, Philippa Hand, Kate Higgs, Alia Munir, Jenny Prinn, David Mark Pritchard, Debashis Sarker, Rajaventhan Srirajaskanthan, Catherine Bouvier Ellis
Neuroendocrine neoplasms: Consensus on a patient care pathway. Journal of neuroendocrinology 36 (4) (2024)
Jessica Hooper, Nikie Jervis, Lucy Morgan, Vivienne Beckett, Philippa Hand, Kate Higgs, Alia Munir, Jenny Prinn, David Mark Pritchard, Debashis Sarker, Rajaventhan Srirajaskanthan, Catherine Bouvier Ellis
Neuroendocrine neoplasms: Consensus on a patient care pathway. Journal of neuroendocrinology (2024)
Remi Samain, Oscar Maiques, Joanne Monger, Hoyin Lam, Juliana Candido, Samantha George, Nicola Ferrari, Leonie KohIhammer, Sophia Lunetto, Adrian Varela, Jose L Orgaz, Felip Vilardell, Jorge Juan Olsina, Xavier M Guiu, Debashis Sarker, Adrian Biddle, Frances R Balkwill, Jim Eyles, Robert W Wilkinson, Hemant Mahendrakumar Kocher, Fernando Calvo, Claire M Wells, Victoria Sanz-Moreno
CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells. Science advances 9 (42) (2023)
Cienne Morton, Richard Sullivan, Debashis Sarker, John Posner, James F Spicer
Revitalising cancer trials post-pandemic: time for reform. British journal of cancer (2023)
Cienne Morton, Richard Sullivan, Debashis Sarker, John Posner, James F Spicer
Revitalising cancer trials post-pandemic: time for reform. British journal of cancer (2023)
Rebecca S Kristeleit, Ruth Plummer, Robert Jones, Louise Carter, Sarah P Blagden, Debashis Sarker, Tobias Arkenau, Thomas R Jeffry Evans, Sarah Danson, Stefan N Symeonides, Gareth J Veal, Barbara J Klencke, Mark M Kowalski, Udai Banerji
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British journal of cancer (2023)
Robert Jones, Ruth Plummer, Victor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca S Kristeleit, Debashis Sarker, Hendrick-Tobias Arkenau, Patricia Roxburgh, Harriet Sarah Walter, Sarah P Blagden, Alan Anthony, Barbara J Klencke, Mark M Kowalski, Udai Banerji
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Jessica K Nelson, May Zaw Thin, Theodore Evan, Steven Howell, Mary Y Wu, Bruna Almeida, Nathalie Legrave, Duco S Koenis, Gabriela Koifman, Yoichiro Sugimoto, Miriam Llorian Sopena, James I MacRae, Emma Nye, Michael Howell, Ambrosius P Snijders, Andreas Prachalias, Yoh Zen, Debashis Sarker, Axel Behrens
USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer. Nature communications 13 (1) (2022)
Jörg Trojan, Patrick Mollon, Bruno Daniele, Florence Marteau, Lidia Martín, Yuxin Li, Qing Xu, Piscaglia Fabio, Renata Zaucha, Debashis Sarker, Ho Yeong Lim, Marino Venerito
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison. Advances in therapy 38 (5) (2021)